# ALPHAEON Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alphaeon

- Industry: Healthcare
- Headquarters: Irvine, US
- Website: www.alphaeon.com
- Total disclosed funding: $107M
- Latest round: Series B (Nov 10, 2015)
- Investors on record: 4

## About

ALPHAEON Corporation is a healthcare company that specializes in innovative aesthetic and ophthalmic products, offering advanced surgical technologies and patient care solutions to enhance medical outcomes.ALPHAEON Corporation, founded in 2013, is headquartered in Irvine, US. The company focuses on delivering healthcare solutions in aesthetic and ophthalmic sectors. The CEO is Thomas Ervesun. ALPHAEON has completed a total of 5 deals, with the most recent deal occurring on May 7, 2017. The company raised USD 5.50 mn in a VENTURE DEBT round, contributing to a total of USD 80.06 mn raised in funding.ALPHAEON specializes in providing innovative solutions primarily within the healthcare sector, focusing on aesthetic and ophthalmic products and services. The company’s core offerings include advanced surgical technologies and patient care solutions designed to address various medical and aesthetic needs. Their products aim to enhance patient outcomes in procedures such as laser eye surgery and cosmetic enhancements, with a strong emphasis on safety and efficacy. Targeted primarily towards healthcare providers, including hospitals and clinics, ALPHAEON serves a diverse client base that encompasses both practitioners and patients seeking enhanced aesthetic experiences. Their products are marketed across several key geographical regions, including North America, Europe, and parts of Asia, positioning them strategically within the global healthcare landscape.ALPHAEON generates revenue through a structured model that includes direct sales to healthcare providers and partnerships with medical professionals. Transactions typically occur through B2B engagements, where clinics and hospitals purchase ALPHAEON's products to incorporate into their service offerings, ensuring that they meet patient demands for advanced aesthetic and ophthalmic solutions. The company’s flagship products often command premium pricing due to their innovative technology and the value they provide in enhancing patient care. Revenue is further supplemented through ongoing support services and training programs for medical staff, creating a comprehensive ecosystem around its product offerings. This multifaceted revenue stream underscores ALPHAEON’s commitment to fostering long-term relationships with its partners while delivering high-quality healthcare solutions.In May 2017, ALPHAEON Corporation raised USD 5.50 mn in VENTURE DEBT financing led by returning investor Dental Innovations BVBA, with participation from Longitude Capital, Sailing Capital, and other unspecified investors. The funding will be utilized to develop new aesthetic and ophthalmic products, with plans to expand into emerging markets in Asia and Europe by 2020. The company is focused on enhancing its product line and increasing its market presence, ensuring alignment with evolving healthcare needs.

## Funding rounds

- Series B, Nov 10, 2015, $80M — Longitude Capital, Sailing Capital, Chow Tai Fook Enterprises, H&S Ventures
- Series A, Jan 14, 2015, $27M — Longitude Capital

## Investors

- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Sailing Capital (https://capitalatlas.ai/funds/sailing-capital) — Series B
- Chow Tai Fook Enterprises — Series B
- H&S Ventures — Series B